Edition:
United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

1.11AUD
23 Sep 2016
Change (% chg)

$-0.00 (-0.45%)
Prev Close
$1.12
Open
$1.13
Day's High
$1.13
Day's Low
$1.10
Volume
816,563
Avg. Vol
1,206,294
52-wk High
$3.78
52-wk Low
$1.01

Summary

Name Age Since Current Position

Brian Jamieson

2007 Independent Non-Executive Chairman of the Board

Silviu Itescu

2014 Chief Executive Officer, Executive Director

William Burns

2016 Vice Chairman of the Board

Paul Hodgkinson

2014 Group Chief Financial Officer

Charlie Harrison

2014 Company Secretary

Donal O'Dwyer

62 2014 Non-Executive Independent Director

Eric Rose

65 2014 Non-Executive Independent Director

Michael Spooner

2014 Non-Executive Independent Director

Ben-Zion Weiner

71 2014 Non-Executive Independent Director

Julie Meldrum

Global Head - Corporate Communications

Biographies

Name Description

Brian Jamieson

Mr. Brian Jamieson, FCA, has been Independent Non-Executive Chairman of the Board of Mesoblast Ltd., since November 22, 2007. He was Chief Executive of Minter Ellison Melbourne and a partner of the Minter Ellison Revenue Group from 2002 to 2005. Mr. Jamieson retired as Chief Executive of Minter Ellison Melbourne on December 31, 2005. Prior to joining Minter Ellison, he was Chief Executive Officer at KPMG Australia from 1998 to 2000, Managing Partner of KPMG Melbourne and Southern Regions from 1993 to 1998 and Chairman of KPMG Melbourne from 2001 to 2002. Mr. Jamieson was also a KPMG Board Member in Australia, and a member of the USA Management Committee. He is Chairman of Sigma Pharmaceuticals Limited and a Non-Executive Director of the Tatts Group Limited. Mr Jamieson is also a Director and Treasurer of the Bionic Ear Institute. He is a fellow of the Institute of Chartered Accountants in Australia and a Member of the Institute of Company Directors.

Silviu Itescu

Prof. Silviu Itescu is Chief Executive Officer, Executive Director of Mesoblast Ltd., Prior to founding Mesoblast in 2004, he established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr. Itescu has been a faculty member of Columbia University in New York, and the University of Melbourne and Monash University in Australia. In 2013, Dr. Itescu received the inaugural Key Innovator Award from the Vatican’s Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy. In 2011, he was named BioSpectrum Asia Person of the Year. Dr. Itescu has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the Board of Directors of several publicly listed life sciences companies.

William Burns

Mr. William (Bill) A. Burns has been appointed as Vice Chairman of the Board of the Company. He was Non-Executive Independent Director of Mesoblast Ltd., with effect from March 6, 2014. Mr Burns brings to Mesoblast extensive international commercial, business development, and operational experience in the pharmaceutical industry. From 1991-1998, he was Global Head of Strategic Marketing and Business Development at F. Hoffmann-La Roche Ltd. From 2000-2009, Mr Burns was a Member of the Corporate Executive Committee of the Roche Group and from 2001-2009, he was CEO of Roche Pharmaceuticals. During this time, Mr Burns had significant involvement in the privatization of Genentech, the integration of Boehringer Mannheim and the negotiations that resulted in Roche becoming a majority owner of Chugai Pharmaceuticals in Japan. Mr Burns has been a non-executive Director of Chugai Pharmaceuticals (2001-2014), Genentech (2004-2014), Roche (2010-2014), and Shire Pharmaceuticals plc since 2010, most recently as Senior Independent Non-Executive Director. His other key appointments in healthcare include roles as Vice Chairman, Vestergaard, Governor and Trustee for Wellcome Trust, Trustee for the Institute of Cancer Research, London, and Scientific Advisory Board Member for the University of Cologne/Bonn Center for Integrated Oncology.

Paul Hodgkinson

Mr. Paul Hodgkinson has been appointed as Group Chief Financial Officer of Mesoblast Limited., with effect from 25 August 2014. Mr Hodgkinson has broad and high-level international pharmaceutical experience in all aspects of finance, strategic planning, business development and licensing, manufacturing and supply chain, and procurement. From 2011 to 2014, Mr Hodgkinson was Chief Financial Officer and had full financial responsibility for the Novartis ANZ Group of companies and divisions comprising Pharmaceuticals, Alcon, Sandoz, Vaccines and Diagnostics, Consumer and Animal Health. Previously, he held a number of leadership roles with AstraZeneca in the United Kingdom, including Global Licensing Finance Director, before being appointed Chief Financial Officer for AstraZeneca Australia from 2006 to 2011.

Charlie Harrison

Mr. Charlie Harrison has been appointed as Company Secretary of Mesoblast Limited., with effect from 1 September 2014. Mr. Harrison joined Mesoblast as a legal counsel in 2013. He was previously a senior associate at the international law firm Allens, working in their Hong Kong and Melbourne offices for nine years as a corporate lawyer. Mr. Harrison has an Arts/Law degree from the University of Melbourne.

Donal O'Dwyer

Mr. Donal P. O'Dwyer is Non-Executive Independent Director of Mesoblast Ltd. He has over 25 years of experience as a senior executive in the global cardiovascular and medical devices industries. From 1996 to 2003, Mr O’Dwyer worked for Cordis Cardiology, the cardiology division of Johnson & Johnson’s Cordis Corporation, initially as its president (Europe) and from 2000 as its worldwide president. Prior to joining Cordis, he worked for 12 years with Baxter Healthcare, rising from plant manager in Ireland to president of the Cardiovascular Group, Europe, now Edwards Lifesciences. He is a qualified civil engineer, has a MBA and is on the Board of Directors of a number of life sciences companies including Cochlear Limited, Atcor Medical Holdings Ltd and Fisher & Paykel Healthcare Ltd.

Eric Rose

Dr. Eric A. Rose, M.D., has been Non-Executive Independent Director of Mesoblast Ltd. He is currently Chairman and Chief Executive Officer of SIGA Technologies and Executive Vice President, Life Sciences at MacAndrews & Forbes, Inc., the holding company of Ronald O. Perelman. From 2008 through 2012, Dr Rose served as the Edmond A. Guggenheim Professor and Chairman of the Department of Health Evidence and Policy at the Mount Sinai School of Medicine. From 1994 through 2007, he served as Chairman of the Department of Surgery and Surgeon-in-Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital. From 1982 through 1992, Dr Rose led the Columbia Presbyterian heart transplantation program in the United States. He currently sits on the Board of Directors of ABIOMED.

Michael Spooner

Mr. Michael R. Spooner is Non-Executive Independent Director of Mesoblast Ltd. During this period he has filled various roles including as Chairman from the date of the ASX public listing in 2004 until 2007, Chair of the Audit and Risk Committee as well as a member of the Remuneration Committee. Over the past several years Mr Spooner has served on the Board of Directors in various capacities at several Australian and international biotechnology companies, including BiVacor Pty Ltd (2009-2013), Advanced Surgical Design & Manufacture Limited (2010-2011), Peplin, Inc. (2004-2009), Hawaii Biotech, Inc. (2010-2012), Hunter Immunology Limited (2007-2008), and Ventracor Limited (2001-2003). Prior to returning to Australia in 2001, he spent much of his career internationally where he served in various roles including as a partner to PA Consulting Group, a United Kingdom-based management consultancy and a Principal Partner and Director of Consulting Services with PricewaterhouseCoopers (Coopers & Lybrand) in Hong Kong. In addition, Mr Spooner has owned and operated several international companies providing services and has consulted to a number of American and Asian public companies.

Ben-Zion Weiner

Dr. Ben-Zion Weiner, ph.D., has been Non-Executive Independent Director of Mesoblast Ltd since May 9, 2012. In a 37-year career at Teva Pharmaceutical Industries Ltd, he held various senior research and development positions, including Senior Vice President of Global Research and Development. Dr Weiner twice received the Rothschild Prize for industrial innovation – for the development of Copaxone for the treatment of multiple sclerosis, and alpha D3 for kidney and bone disorders. He is on the Board of Directors at Novaremed Ltd., the scientific advisory board at E-QURE Corp. and Breed IT, Corp. and has served on the Board of Directors at Geffen Biomed Investments Ltd (2010-2013), XTL Biopharmaceuticals Limited (2012-2013) and Breed IT, Corp.

Julie Meldrum

Basic Compensation

Name Fiscal Year Total

Brian Jamieson

347,103

Silviu Itescu

1,920,910

William Burns

172,077

Paul Hodgkinson

905,196

Charlie Harrison

--

Donal O'Dwyer

176,021

Eric Rose

186,049

Michael Spooner

178,759

Ben-Zion Weiner

176,049

Julie Meldrum

--
As Of  29 Jun 2015